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ABSTRACT 
 
Diabetes mellitus (DM), or simply diabetes, is a group of metabolic diseases in which a person has high blood 
sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is 
produced. This high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia 
(increased thirst) and polyphagia (increased hunger). Conventionally, diabetes has been divided into three types 
namely: Type 1 DM or insulin-dependent diabetes mellitus (IDDM) in which body fails to produce insulin, and 
presently requires the person to inject insulin or wear an insulin pump. This is also termed as "juvenile diabetes". 
Type 2 DM or non-insulin-dependent diabetes mellitus (NIDDM), results from insulin resistance, a condition in 
which cells fail to use insulin properly, with or without an absolute insulin deficiency. This type was previously 
referred to as or "adult-onset diabetes". The third main type is gestational diabetes which occurs when women 
without a previous history of diabetes develop a high blood glucose level during her pregnancy. It may precede 
development of type 2 DM. Currently available pharmacotherapy for the treatment of diabetes mellitus includes 
insulin and oral hypoglycemic agents. Such drugs acts by either increasing the secretion of insulin from pancreas or 
reducing plasma glucose concentrations by increasing glucose uptake and decreasing gluconeogenesis. However 
these current drugs do not restore normal glucose homeostasis for longer period and they are not free from side 
effects such as hypoglycemia, kidney diseases, GIT problems, hepatotoxicity, heart risk problems, insulinoma and 
they have to take rest of life. Various herbal drugs have been also proved effective due to their beneficial contents 
in treatment of diabetes. The present review therefore is an attempt to focus on the physiological aspects of 
diabetes, its complications, goals of management, and synthetic and herbal treatment of diabetes.  
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Introduction 
 
Diabetes mellitus is a metabolic disorder initially 
characterized by a loss of glucose homeostasis with 
disturbances of carbohydrate, fat and protein 
metabolism resulting from defects in insulin secretion, 
insulin action, or both. Without enough insulin, the 
cells of the body cannot absorb sufficient glucose from 
the blood; hence blood glucose levels increase, which 
is termed as hyperglycemia. If the glucose level in the 
blood remains high over a long period of time, this can 
result in long-term damage to organs, such as the  
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kidneys, liver, eyes, nerves, heart and blood vessels. 
Complications in some of these organs can lead to 
death. Diabetes Mellitus is a constitutional disease. It 
is also known as “Disease of Civilization” 
(Urbanization) seen more in cities than villages. But 
however it is now making inroads into Indian villages. 
Diabetes is an important human ailment afflicting 
many from various walks of life in different countries. 
It is an outcome of sedentary life style & incorrect 
food habits. No. of people afflicted by Diabetes 
Mellitus is increasing each day. 9-12% population of 
world has either established Diabetes Mellitus (or) 
tendency of contracting it in near future.18 Millions of 
Indians are suffering from Diabetes Mellitus. Though 
it is rampant today, it is not a new disease. It is well-
known from historic times. Well known ayurvedic 
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physicians MaharshiCharaka(600BC) &Sushrutha 
(400BC) correctly described almost all the symptoms 
of this disease  and called it as “MadhuMeha”(a 
shower of honey) and explained in ayurvedic literature 
called „SushruthaSamhitha‟[1-6]After the discovery of 
insulin, people had started believing that Diabetes 
Mellitus will soon be banished from the earth. 
However this belief has turned out to be a dream & 
proved fallacious.  With vigorous treatment, short-
term complications of Diabetes Mellitus can be 
checked; but its long-term complications can be hardly 
being prevented. Diabetes is one of the oldest known 
diseases. An Egyptian manuscript from c. 1550 BCE 
mentions the phrase “the passing of too much 
urine”.The great Indian physician Sushruta identified 
the disease and classified it as Medhumeha.
.
 The 
ancient Indians tested for diabetes by observing 
whether ants were attracted to a person's urine, and 
called the ailment "sweet urine disease" 
(Madhumeha)[7-10].  
Concerning the sweetness of urine, it is to be noted 
that the Chinese, Japanese and Korean words for 
diabetes are based on the same ideographs which mean 
"sugar urine disease". It was in 1776 that Matthew 
Dobson confirmed that the sweet taste comes from an 
excess of a kind of sugar in the urine and blood. The 
first complete clinical description of diabetes was 
given by the Ancient Greek physician Aretaeus of 
Cappadocia (fl. 1st century CE), who noted the 
excessive amount of urine which passed through the 
kidneys and gave the disease the name 
“diabetes.”Diabetes mellitus appears to have been a 
death sentence in the ancient era. Hippocrates makes 
no mention of it, which may indicate that he felt the 
disease was incurable. In medieval Persia, Avicenna 
(980–1037) provided a detailed account on diabetes 
mellitus in The Canon of Medicine, "describing the 
abnormal appetite and the collapse of sexual 
functions," and he documented the sweet taste of 
diabetic urine.   Avicenna recognized a primary and 
secondary diabetes. He also described diabetic 
gangrene, and treated diabetes using a mixture of 
lupine, trigonella (fenugreek), and zedoary seed, 
which produces a considerable reduction in the 
excretion of sugar, a treatment which is still prescribed 
in modern times. Avicenna also "described diabetes 
insipidus very precisely for the first time", though it 
was later Johann Peter Frank (1745–1821) who first 
differentiated between diabetes mellitus and diabetes 
insipidu.[5,6,11-13] 
Although diabetes has been recognized since antiquity, 
and treatments of various efficacy have been known in 
various regions since the Middle Ages, and in legend 
for much longer, pathogenesis of diabetes has only 
been understood experimentally since about 1900
. 
In 
1910, Sir Edward Albert  Sharpey-Schafer suggested 
that people with diabetes were deficient in a single 
chemical that was normally produced by the pancreas; 
he proposed calling this substance insulin, from the 
Latin insula, meaning island, in reference to the 
insulin-producing islets of Langerhans in the 
pancreas.Insulin production and therapy rapidly spread 
around the world, largely as a result of this decision. 
Banting is honored by World Diabetes Day which is 
held on his birthday, November14.The distinction 
between what is now known as type 1 diabetes and 
type 2 diabetes was first clearly made by Sir Harold 
Percival (Harry) Himsworth, and published in January 
1936.Despite the availability of treatment, diabetes has 
remained a major cause of death. For instance, 
statistics reveal that the cause-specific mortality rate 
during 1927 amounted to about 47.7 per 100,000 
population in Malta.[3,4,14-17]
 
Epidemiology of diabetes mellitus 
The prevalence of diabetes mellitus is increasing with 
ageing of the population and lifestyle changes 
associated with rapid urbanization and westernization. 
The disease is found in all parts of the world and is 
rapidly increasing in its coverage [18-20]. 
Prevalence and incidence of diabetes mellitus 
Globally, the prevalence of diabetes without type 
distinction, was estimated to be 4% in 1995. According 
to WHO, it is estimated that 3% of the world‟s 
population have diabetes and the prevalence is 
expected to double by the year 2025 to 6.3%. There 
will be a 42% increase from 51 to 72 million in the 
developed countries and 170% increase from 84 to 228 
million, in the developing countries. Thus, by the year 
2025, over 75% of all people with diabetes will be in 
the developing countries, as compared to 62% in 1995.  
The reasons behind this projected increase in 
prevalence rate are due to urbanization, westernization 
and their associated lifestyle changes, increase in life 
expectancy at birth, physical inactivity and obesity and 
possibly a genetic predisposition. Age, ethnic, regional 
and racial differences have also been found to play a 
role for the diabetic incidence in heterogeneous 
populations within the same area [21-23]. 
Types of Diabetes Mellitus 
Diabetes results in the impairment of the body‟s ability 
to use food because either the pancreas does not make 
insulin or the body cannot use insulin properly. 
Hypoglycemia (low blood glucose) is most commonly 
seen in diabetic patients, when the body gets too much 
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insulin, too little food, a delayed meal, or more than the 
usual amount of exercise. When the body gets too little 
insulin, too much food, or too little exercise, it results 
in hyperglycemia (high blood glucose). Stress may 
contribute to hyperglycemia. Hyperglycemic state 
(diabetes mellitus) arises when the blood glucose 
(sugar) levels are higher than 180 mg/dl (10 mmol/l). 
Diabetes is of mainly three types. They are type-1 
diabetes (T1D), type-2 diabetes (T2D) and gestational 
diabetes mellitus. T1D, also called as the insulin-
dependent diabetes mellitus (IDDM), manifests due to 
the autoimmune damage of the β-cells which then leads 
to the suppression or cessation of insulin production. 
T1D is also called the “juvenile diabetes”. T2D, also 
called as the adult-onset diabetes or non-insulin-
dependent diabetes mellitus (NIDDM) among humans 
is caused by either low levels or absence of insulin or 
insulin resistance (IR). Gestational diabetes mellitus 
(GDM) is defined as glucose intolerance of varying 
degrees, which appears, or is first diagnosed, during 
pregnancy and may or may not persist after delivery. 
The type 1 diabetes mellitus (T1DM) is a multifactorial 
autoimmune disease characterized by chronic 
hyperglycemia and by the development of specific 
vascular alterations. Autoimmune destruction of β-cell 
by T-cells, is responsible for T1DM which results in 
severe insulin depletion. It is also known as juvenile 
diabetes. 
Type 2 diabetes mellitus (T2DM) is a chronic disease 
characterized by insulin resistance, which leads to 
hyperglycemia. More than 180 million people 
worldwide have diabetes as estimated by The World 
Health Organization (WHO). T2DM is expected to 
reach pandemic levels, rising from 171 million in 2000 
to 366 million in 2030. T2DM is the more prevalent 
form and accounts 90% of all diabetes cases 
worldwide. The key features of type 2 diabetes is 
insulin resistance associated with obesity due to the 
release of free fatty acids (FFA) and the release of 
inflammatory cytokines from the expanded adipose 
tissue mass.The decreased ability of insulin to regulate 
glucose metabolism is known as insulin resistance. 
Intracellular lipid accumulation occurs due to increased 
import of FFA into nonadipose tissues. Ragheb R et al. 
reported that disturbances of lipids in the body lead to 
development of insulin resistance and metabolic 
diseases [24-28]. 
Gestational Diabetes Mellitus (GDM) occurs in 
approximately 7% of pregnancies and there is a greater 
risk of morbidity and mortality to mother, fetus and 
subsequent neonate. Intensive monitoring and 
treatment is necessary for GDM. Women with the 
history of gestational diabetes mellitus (GDM) have a 
significantly increased risk of type 2 diabetes and of 
cardiovascular disease during the next years after 
delivery [23-32]. 
Factors Causing Diabetes 
T1DM is mainly triggered by environmental factors. 
The main factors that contribute to the development of 
insulin resistance (T2DM) include obesity, physical 
inactivity, and smoking. The prevalence of diabetes 
mellitus is increasing due to urbanisation, 
westernisation and their associated lifestyle changes 
(nutritional habits, lack of adequate dietary intake and 
low physical activity) accompanied by obesity, and low 
socioeconomic level. Body weight is one of the most 
important modifiable risk factors in T2DM. Obesity is 
an independent risk factor for dyslipidaemia, 
hypertension and cardiovascular disease and increases 
the risk of cardiovascular complications and mortality 
in patients with T2DM. Age is another factor that is 
associated with T2DM. The pancreas of an aged person 
doesn‟t pump insulin as efficiently as it did in younger 
ones. High blood pressure and high cholesterol also 
contribute to T2DM. 
Mutations in insulin gene and insulin receptors also 
contribute to type 2 diabetes. Sphingosine-1-phosphate 
(S1P) is an important bioactive phospholipid with a 
wide range of cellular functions. In individuals with 
T2D, S1PR2 was shown to be down-regulated in 
platelets. S1PR2 variant Val→Ala at position 286 
associated significantly with the incidence of diabetes. 
Novel Val→Ala polymorphism at position 286 in the 
NPXXY motif of S1PR2 is significantly associated 
with incidence and age at onset of diabetes in the 
LURIC study cohort. Hepatic insulin sensitivity in 
young human subjects tends to be reduced with 
TCF7L2 (Transcription factor 7-like 2) gene 
polymorphism whereas peripheral increased insulin 
sensitivity is observed in older human individuals. It is 
very difficult to map genes related to T2DM in 
humans, because environmental factors such as dietary 
intake and life style, influence the genetic effects of 
T2DM. The hepatocyte nuclear factor 4-α (HNF4α) 
gene codes for a transcription factor which is 
responsible for regulating gene transcription in 
pancreatic beta cells. HNF4α has also been associated 
with the regulation of glucose transport and 
metabolism. Disruptions in this gene can lead to 
(MODY), an autosomal dominant, non-insulin 
dependent form of diabetes known as maturity onset 
diabetes of the young (MODY)[33-36].  
Complications 
Diabetes is root cause for several serious complications 
such as cardiovascular diseases, cerebrovascular 
diseases, renal disorders, inflammation and immunity, 
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and obesity. Epidemiological studies of diabetes 
mellitus have shown that gender, age, and ethnic 
background are important factors when considering the 
development of diabetes mellitus and its complications. 
Amadori glucose adducts modifies albumin into 
glycated albumin, which is associated independently 
with diabetes complictions. The diabetes complications 
are equally associated with the both types of DM. 
Defects in insulin metabolism and dysfunction in 
carbohydrate, lipid and protein metabolism leads to 
high blood levels of glucose which results in long-term 
complications. Diabetic complications include 
hypertension, retinopathy, end-stage renal disease, 
neuropathy, peripheral vascular disease, electrolyte 
imbalance, immune suppression, erectile dysfunction, 
and complications of pregnancy. 
Diabetes leads to increased levels of endothelial micro 
particles. Diabetic ketoacidosis (DKA) is a serious 
condition caused by hyperglycemia, if the patient is not 
treated over a period of days. It is characterized by 
nausea, vomiting, and a high level of ketones in the 
blood and urine. Addison‟s disease, Grave‟s 
hyperthyroidism, hypothyroidism, hypogonadism, 
coeliac disease, pernicious anaemia and vitiligo are 
some of the autoimmune disorders associated with 
diabetes. Keratoconus is a non-inflammatory corneal 
disease seen in some diabetic patients. Hypoglycemia 
causes insulinoma, an islet beta cell-derived tumor 
manifesting various clinical symptoms. Insulinoma is 
diagnosed by the measurement of proinsulin. 
Decreased number of pump units on the erythrocyte 
membrane, altered lipid – protein interaction, depleted 
membrane anionic charge and enzyme glycation and 
peroxidation contribute to many abnormal 
complications in Diabetes mellitus. Na+K+-ATPase a 
membrane bound enzyme that energizes the Napump 
by hydrolyzing ATP is associated with action of 
insulin. Lack of insulin decreases Na+K+-ATPase 
activity which can cause obesity- one of the major 
causes for type2 diabetes mellitus.[37-40] 
Secondary carnitine deficiency is commonly seen in 
T1DM. Most of the disorders of fatty acid metabolism 
are associated with abnormal carnitine or acylcarnitine 
levels and recurrent hypoglycemia. Medium chain 
acyl-CoA dehydrogenase deficiency (MCADD) is the 
most common among them occurs during a prolonged 
fast or during acute illness. A significant reduction in 
HbA1c was seen in patients with carnitine deficiency. 
MODY is an autosomal dominant single gene 
hereditary disease and account for about 2% - 5% of 
type 2 diabetes. It usually appears before the age of 25 
and occurs mostly in children and adolescents, 
characterized by β cell disfunction. Isoleucine, citrate, 
inositol, 1-methylhistidine and tyrosine are the 
differential metabolites considered biomarkers for 
predicting probable MODY.Western life style nutrition 
is associated with increased insulin/IGF-1 signaling 
that results in acne formation. Endocrine disorders with 
increased levels of insulin and/or IGF-1 and insulin 
resistance are often associated with acne like HAIR-
AN (hyperandrogenism, insulin resistance, 
acanthosisnigricans) syndrome. It is clearly evident that 
in many cases of psoriasis, diabetes is a major co-
morbidity along with hypertension. Several systemic 
diseases associated with syringomas (tumours) were 
reported in patients with diabetes mellitus[41-43]. 
Diabetic retinopathy 
Diabetic retinopathy (DR) is damage to the eye's retina 
that occurs with long-term diabetes. Diabetic 
retinopathy is is the most common cause of blindness 
in most of the countries. It is commonly seen in both 
type 1(40%) and type 2 DM (20%). There are two 
types of diabetic retinopathy. They are 
Nonproliferative which develops first, Proliferative is 
the more advanced and severe form of the disease. In 
patients with T2DM involvement of fovea by edema 
and hard exudates or ischemia is the most common 
cause of visual impairment. Hyperglycemia and the 
increased duration of diabetes are the major risk factors 
for DR. Other risk factors include hypertension, 
hyperlipidemia, pregnancy, and microalbuminuria. 
Symptoms of diabetic retinopathy appears only after 
the damage occurs to eyes which include- Blurred 
vision and slow vision loss over time, floaters, 
Shadows or missing areas of vision, trouble seeing at 
night. The vascular commitment is the most serious 
and common condition in DM. The factors for vascular 
damage of DM include poor glycemic control, 
lipoprotein abnormalities, hypertension, oxidative 
stress (OS), inflammation and advanced glycation end-
products (AGEs). Retinopathy is characterized by 
increased vascular permeability, by vascular closure 
mediated by the formation of new blood vessels- 
neovascularization, on the retina and posterior surface 
of the vitreous. Generally, neovascularization results 
from occlusion of fragile capillaries and frequently 
originate pre-retinal and vitreous hemorrhage in case of 
vitreous detachment. Much attention has been focused 
on the role of OS in the pathogenesis of diabetic 
complications is of much importance. The retina is 
highly susceptible to OS and the oxidation products are 
toxic to the microvascular walls and therefore results in 
diabetic microvascular damage. Diagnosis of 
retinopathy is based on finding the diagnostic signs of 
retinopathy on eye exams by fundoscopy[44-46]. 
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Diabetic maculopathy 
Diabetic maculopathy is most commonly seen in 
T2DM whereas macular ischemia is more frequently 
seen in T1DM. Diabetic maculopathy consist of 
macular edema and ischemia[44,47]. 
Macular ischemia 
Macular ischemia is a devastating condition that causes 
irreversible visual loss. It is seen mostly in T1DM. 
Basement membrane thickening, increased viscosity of 
blood and endothelial cell damage occurs in the 
pathogenesis of macular ischemia[48-50]. 
Diabetic macular edema 
Diabetic macular edema is the leading cause of visual 
loss in patients with non proliferative diabetic 
retinopathy. DME is the consequence of accumulation 
of fluid in the retina after dysfunction of the blood 
retinal barrier. Breakdown in blood retinal barrier at the 
level of the perifoveal vessels results in edema[51,52]. 
Cataract 
Cataract develops at an earlier age in diabetic patients 
which is characterized by clouding of the eye lens. In 
cataract the lens becomes opaque, reducing the amount 
of light reaching the retina. Connexins (Cx) are a 
family of proteins that forms hemichannels that 
communicate the cytoplasm with the extracellular 
space. Under oxidative stress conditions such as 
diabetes, it is possible that Cx oxidation may contribute 
to cataract formation. Neurotrophic corneal ulcers may 
develop in patients with DM[53-55]. 
Glaucoma 
Glaucoma is a condition in which increase in fluid 
pressure inside the eye leads to optic nerve damage and 
loss of vision. A person with diabetes is more prone to 
get glaucoma compared to others[56,57]. 
Cardiovascular diseases associated with diabetes 
Cardiovascular disease is the leading cause of 
morbidity and mortality in patients with diabetes 
mellitus. Patients with diabetes mellitus have a 2 to 4 
times higher risk of cardiovascular disease and up to a 
3 times increase in mortality than non diabetics. 
Increased body mass index, diabetes, 
hypercholesterolemia, smoking, male-sex, family 
history and age are the risk factors for coronary heart 
disease and atherosclerosis. Increased pulse pressure 
causes stiffening of arteries which is an independent 
risk factor for cardiovascular diseases. Use of LXR-
alpha ligands may be beneficial for the treatment of 
diabetes induced Coronary Artery Disease. Some 
studies confirmed that the risk factor burden tended to 
be higher among women, with a greater prevalence of 
obesity and trends toward higher rates of hypertension, 
diabetes mellitus and home stress. Atherosclerosis, 
coronary artery disease myocardial infarction are the 
commonly associated cardiovascular diseases in 
diabetic patients. Individuals with T2DM are at higher 
risk of cardiovascular diseases (CVD) than those 
without T2DM. Diabetes, dyslipidemia, hypertension 
and obesity are well-known major and independent 
cardiovascular risk factors. Diabetes mellitus is also a 
strong and independent risk factor for congestive heart 
failure. Disturbed conductibility of the left ventricle 
(LV) is the characteristic feature of this common 
complication. Hyperosmolarity is a condition of higher 
osmolarity commonly seen in diabetic patients. Hong 
Chen et al. reported that cardiovascular eNOS, HO and 
HSP90 were induced by hyperosmolarity in DM. The 
heart rate and blood pressure is generally altered in 
response to changes in arterial wall tension detected by 
the arterial baroreceptors in the carotid sinus and aortic 
arch by a mechanism known as Arterial baroreflex. 
Endogenous Ang II-NADPH oxidase-superoxide 
signaling is over-activated in the nodose ganglia, which 
contributes to the attenuated arterial baroreflex 
function in the diabetes. Cardiovascular disease, 
particularly coronary artery disease, is a major cause of 
morbidity and mortality among patients with diabetes 
mellitus. Atrial Fibrillation (AF) is associated with 
diabetes due to increased oxidant stress. Shock therapy 
is used for supra ventricular arrhythmias including 
atrial fibrillation (AF), atrial flutter, etc. There is also 
evidence that hyperglycemia may induce diabetic 
angiopathy through the generation of OS or through the 
accumulation of AGEs, leading to nitrous oxide 
systems (NOS) [58-62]. 
Atherosclerosis is characterized by chronic 
inflammation affecting the arterial intima. Low plasma 
HDL cholesterol (HDL-C) is consistently associated 
with increased risk of atherosclerotic disease [63]. 
Diabetes patients have low levels or impaired HDL 
(High density lipid protein) metabolism. The increased 
pulse pressure (PP) was an effect of the atherosclerotic 
disease. Hyperinsulinemia, a major feature of T2DM 
and the meta¬bolic syndrome, is believed to be highly 
associated with the occurrence of atherosclerosis and 
vascular restenosis. Increased neointima formation 
caused by vascular injury via potentiating smooth 
muscle cell migration and pro¬liferation is commonly 
seen in patients with hyperinsulinemia. The application 
of insulin sensitizers, such as synthetic 
thiazolidinediones (STD), significantly reduces carotid 
artery intima/ media thickness in patients with T2DM 
[64-67].Left ventricular (LV) hypertrophy is a potent 
independent risk factor for cardiovascular morbidity 
and mortality caused due to hypertension and obesity. 
The association between LV hypertrophy and impaired 
glucose tolerance was described by several 
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epidemiological studies. Increased LV mass is a main 
risk factor for cardiac events such as myocardial 
infarction and heart failure. Previously it was described 
in many studies that the association between DM and 
cardiac abnormalities is more evident in women than 
men. Alexander Riad et al. showed that this association 
is equal in both women and men [68,69].Obesity is 
associated with an increase risk for cardiometabolic 
diseases such as atherosclerosis and T2DM. Oxidative 
stress results of an imbalance between the production 
and degradation of reactive oxygen species such as 
hydrogen peroxide (H2O2). Glutathione peroxidase 
(GPx) regulates the concentration of H2O2. A 
modification in GPx levels affects directly the 
intracellular level of peroxides; a slow-down of its 
activity allows higher intracellular concentration of 
peroxides whereas a stimulation of GPx activity leads 
to lower H2O2 concentration. High GPx activity is 
associated with numerous potentially clinically relevant 
cardiometabolic abnormalities [70-72]. 
Macro-and microvascular complications 
Macro-and microvascular complications are mostly 
seen in diabetic patients. Macrovascular disease 
includes coronary heart disease (CHD), 
cerebrovascular disease, and peripheral vascular 
disease. It is the leading cause of mortality in people 
with diabetes. Microvascular complications include 
effects on small vessels, including arterioles, capillaries 
and venules. Diabetes-related microvascular 
complications are rare in childhood and adolescence. 
Platelets play a key role in the microvascular as well as 
macrovascular complications of diabetic patients. 
Hyperglycemia changes platelet functions by impairing 
calcium homeostasis. Lower fetuinA levels were found 
in Patients with diabetes. Fetuin A is a circulating 
calcium-regulatory glycoprotein that inhibits ectopic 
and vascular calcification. Aortic stenosis (AS) is a 
disease process involving an active calcification of the 
aortic valve (AV). Chronic hyperglycemia is mainly 
involved in the pathophysiology of microangiopathy 
and it is the main cause for diabetes microvascular 
complications. Microalbuminuria, a precursor of 
diabetic nephropathy is associated with a generalized 
endothelial vascular dysfunction. Early diabetes is 
often accompanied by an increased glomerular 
filtration rate (GFR) and hyperfiltration which is 
significantly dependent upon increased NO activity and 
contributes to progression of diabetic nephropathy. 
Serum and urinary NO levels were found to be 
significantly increased in diabetics compared to normal 
individuals [73-75]. 
Diabetic nephropathy 
Diabetic nephropathy is kidney disease or damage that 
occurs in people with diabetes. Diabetic nephropathy is 
one of the most important causes (61%) of endstage 
renal disease that requires renal replacement therapy. 
In people with diabetes, the nephrons thicken and 
slowly become scarred over time. The kidneys begin to 
leak and protein (albumin) passes into the urine. People 
who have more severe kidney disease may have a poor 
appetite, feel tired most of the time, and have a general 
ill feeling. Headache, nausea and vomiting, swelling of 
the legs, and many other symptoms may also occur. 
Clinical progression to diabetic nephropathy is not 
apparently seen in T2DM as it is in T1DM, because of 
the difficulty in determining the acute onset of diabetes 
itself. Sometimes it is difficult to differentiate minimal 
change nephritic syndrome (MCNS) and membranous 
nephropathy (MN) from diabetic nephropathy, 
especially in middle to advanced aged patients with 
T2DM because it does not cause hematuria. Diabetic 
nephropathy was the leading cause of end stage renal 
disease (ESRD) (61%) in patients with Intradialytic 
hypotension (IDH) [76-78]. 
Diabetic neuropathy 
Diabetes mellitus, a common metabolic disease with a 
rising global prevalence, is associated with long-term 
complications of peripheral nervous system and the 
central nervous system. Diabetic neuropathy is a 
common complication of diabetes that results in 
damage to the nerves due to high blood sugar levels for 
a long period of time. There are four types of diabetic 
neuropathy- peripheral, autonomic, proximal, and 
focal. Symptoms of nerve damage include numbness, 
tingling, or pain in the toes, feet, legs, hands, arms, and 
fingers, wasting of the muscles of the feet or hands, 
indigestion, nausea, or vomiting, diarrhea or 
constipation, dizziness or faintness due to a drop in 
blood pressure after standing or sitting up, problems 
with urination, erectile dysfunction in men or vaginal 
dryness in women, weakness [79,80]. 
Stroke is the leading cause of death and disability 
worldwide. Common risk factors for stroke were 
documented including high blood pressure, diabetes, 
previous stroke and myocardial infarction, 
cardiovascular disease, hyperlipidaemia, atrial 
fibrillation, periphery artery occlusive disease (PAOD), 
current smoking and alcohol consumption. 
Spontaneous intracerebral hemorrhage (sICH), defined 
as spontaneous bleeding into the brain, accounts for 
10% to 20% of all strokes is associated with 
diabetes(81, 82). 
Diabetic encephalopathy is also called as 
encephalopathy or malfunction of brain. The 
complications include impaired spatial cognitive 
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functions, memory loss, dementia, coma, seizures and 
death. It involves direct neuronal damage caused by 
intracellular glucose. It is a poor coordination of brain, 
which affects the movements of limbs [83,84].  
Osteoporosis and osteoarthritis 
Diabetes is a higher risk factor for bone and joint 
disorders. Osteoporosis is a thinning of the bones that 
weakens them and increases the risk of fractures. 
Osteoarthritis is a joint disorder caused by the 
degeneration of the joint cartilage between bone 
resulting in joint pain, swelling and stiffness. 
Individuals diagnosed with T1DM are at an increased 
risk of developing osteoporosis, while those with 
T2DM are at an increased risk of osteoarthritis. 
Incidence of osteoporosis and T2DM is known to 
increase in prevalence with aging. Ducy and 
Karsenty‟s group showed that the expression of insulin 
in pancreatic β cells as well as of adiponectin in 
adipocytes is increased by osteocalcin. Recent studies 
have identified osteopathy as a serious complication of 
type 1 and type 2 diabetes. Disruption of insulin and 
insulin-like growth factor 1 (IGF-1) homeostasis in the 
diabetic condition may be responsible for the observed 
skeletal deficits. T2D is not associated with osteopenia 
or osteoporosis, but recent studies have reported that 
subperiosteal porosity is increased in T2D patients who 
fracture. It has been recognized that the alterations in 
mineral and bone metabolism were associated with DM 
and that the resulting bone loss is one of the chronic 
complications of diabetic patients. Both type 1 and type 
2 diabetes are associated with changes in the bone 
mineral density (BMD) and bone turnover markers. 
Bone mineral density (BMD) is reduced in T1D, 
whereas an increased BMD is seen in T2D. An 
increased risk of hip fractures is seen in both T1D and 
T2D, the increase in risk of fractures being more 
pronounced in T1D than in T2D. T2D is a risk factor 
for hip, proximal humerus, and foot fractures among 
older women. Arreola et al. showed a significant 
decrease in both bone mineral content and zinc, 
suggesting that zinc deficiency may be a contributory 
factor to bone loss in T1DM individuals with poor 
glycemic control. Hill et al. showed that zinc stimulates 
osteoblasts in adult‟s withT1DM[85-88].  
Diagnostic Methods of Diabetes 
Diabetes mellitus is diagnosed by demonstrating any 
one of the following methods: 
Fasting plasma glucose level ≥ 7.0 mmol/L (126 
mg/dL) 
Plasma glucose ≥ 11.1 mmol/L (200 mg/dL) 
Glycated hemoglobin (Hb A1C) ≥ 6.5% 
Oral glucose tolerance test (OGTT) 
People with fasting glucose levels from 100 to 125 
mg/dL are considered to have impaired fasting glucose 
also called as pre-diabetes. Fasting plasma glucose is 
mostly preferred because of its low cost and is very 
easy to operate. Diabetes should be confirmed with a 
second test on a different day. The 2-hour oral glucose 
tolerance test (OGTT) is a standard test for diagnosing 
type 2 diabetes but it is expensive and is limited 
because of its labor-intensive multi-blood draw 
protocols. Both the methods require patients to be 
tested in the fasted state. Glycatedhaemoglobin 
(HbA1c) requires only a single point blood draw and is 
more advantageous because it does not require fasting 
blood samples and has higher repeatability. HbA1c is 
an indicator of the average blood glucose concentration 
over the preceding three months and has been proposed 
to be a useful alternative test to screen for type 
2diabetes as it overcomes many of the obstacles 
associated with the OGTT. Glycated hemoglobin is 
better than fasting glucose for determining risks of 
cardiovascular disease and death from any cause. 
HbA1c should be considered in the clinical setting 
because of the greater ease and lower cost of 
measurement. HbA1c has been suggested to be 
superior to FPG for the prediction of vascular disease 
and death from any cause among nondiabetic subjects. 
Latest methods for diagnosis include continuous 
monitoring of interstitial glucose (CGMS) and new 
proposed methods include seven-point self-monitored 
blood glucose (SMBG) profiles along with calculation 
of weekly mean blood glucose (WMG) and glycemic 
variability (GV). A positive association between 
obesity and the risk of developing T2D has been 
consistently observed in many populations. Usual 
anthropometric parameters used to measure obesity are 
BMI (Body Mass Index), WC (Waist Circumference) 
& WHR (Waist Hip Ratio). The most commonly used 
criteria to diagnose obesity are National Cholesterol 
Education Program (NCEP), ATP III criteria. 
According to sensitivity, Pandya et al. suggested WC 
as a better indicator than BMI for diabetes status. The 
American Diabetes Association suggests that 
sudomotor function assessing small fiber status should 
be included in the diagnostic tests for the detection of 
neuropathies in diabetes[89-92].  
Treatment 
The treatment for diabetes mainly involves the 
regulation of blood sugar levels and to prevent diabetic 
complications. Medicines, diet, and exercise are 
included in treatment. Lifestyle modifications and oral 
anti-diabetic medications are recommended for initial 
treatment of DM. 
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Banting and Macleod first discovered the insulin 
hormone. Insulin therapy is required for T1D because 
cells cannot produce insulin. Although cells produce 
insulin harmone in type 2 diabetes but they donot 
respond normally to insulin. In such cases insulin 
therapy helps cells to overcome the resistance to 
insulin. Continuous subcutaneous insulin infusion 
(CSII) is useful therapy for brittle T1D worldwide. The 
frequency of hypoglycemia was decreased and 
improved glycemic variability was achieved with CSII 
therapy which is beneficial to pregnant women with 
diabetes[93-96].  
Insulin Types 
The most commonly-used human insulin preparations 
are Regular (rapid onset of action, short duration of 
action) and NPH (slower onset of action, longer 
duration of action). Regular insulin has an onset of 
action (begins to reduce blood sugar) within 30 
minutes of injection, reaches a peak effect at 1-3 hours, 
and has effects that last 6-8 hours. NPH insulin is 
insulin with an intermediate duration of action. It has 
an onset of action starting about 2 hours following 
injection. It has a peak effect 4-12 hours after injection, 
and duration of action of 18-26 hours. Lente insulin 
also is insulin with an intermediate duration of action. 
It has an onset of action 2-4 hours after injection, a 
peak activity 6-12 hours after injection, and duration of 
action of 18 to 26 hours. Insulin lispro was developed 
by modification at the B26-30 regions of insulin. It was 
approved by the FDA in June, 1996. It was absorbed 
faster and had a shorter duration of action: action 
started within 15 mins of injection, peaked by an hour 
and disappeared within four hours. When lispro was 
modified to a protamine formulation of neutral 
protamine lispro, it gave similar overall glycemic 
control, with improved postprandial glucose. Insulin 
aspart was developed by substituting proline with 
aspartic acid. It has the advantage of reducing the self-
association and enhancing the absorption rate. Insulin 
glargine was developed by elongating the C terminal of 
insulin B chain by two arginine residues: A21 
aspargine residue was substituted with glycine. Insulin 
glargine has a slower onset of action (70 minutes) and 
a longer duration of action (24 hours) than regular 
human insulin. Its activity does not peak. Recent rapid 
acting insulin analogues include Insulin glulisine which 
is by derived from human insulin by the replcement of 
AspB3 by Lys and LysB29 by Glu. Both glulisine and 
lispro are absorbed faster than regular insulin and both 
displayed non-inferiority of glycemic control in all 
types of diabetes. Insulin analogues have so many 
advantages, but they are not used more extensively 
because they are more expensive than regular 
insulins[97,98].  
Intensive glycaemic control in type 2 diabetes 
remarkably reduces the risk of development of 
microvascular complications proved by the United 
Kingdom Prospective Diabetes Study (UKPDS). 
Biphasic insulin aspart 30 (BIAsp 30) (NovoMixR30) 
is an insulin analogue mixture which contains 30% 
unbound rapid-acting insulin aspart and 70% 
intermediate-acting protaminated insulin aspart. 
IMPROVETM reported that Insulin initiation with 
BIAsp 30 is a safe and effective method of insulin 
therapy because it is improved without an increased 
risk of major hypoglycaemic conditions. ArushiSaini et 
al. study demonstrated that once-daily insulin glargine 
may be more efficacious than NPH insulin in the 
treatment of T1D [99,100] 
Riddle et al. have reported that improved glycemic 
control accompanied by weight loss was achieved 
when pramlintide, an amylin analogue, was used in 
combination with insulin glargine. Davidson et al. 
found marked improvement in diabetes control in 
obese, severely insulin resistant T2D patients when U-
500 regular insulin substituted for U-100 NPH insulin. 
Allen Nichol et al. reported that by judicious use of 
these three drugs insulin glargine, U-500 insulin and 
pramlinitide, total number of drugs patient needed to 
control diabetes has been reduced from 5 to 3[34,101]. 
Based on the insulin mechanism of action, various 
drugs have been developed, called insulin 
secretagogues, which stimulate beta cells of pancreas 
for a) secretion of additional insulin e.g. 
sulphonylureas and b) insulin sensitizers e.g. 
metformin. The sensitizers increases action of the 
existing insulin and facilitate greater uptake of glucose 
from plasma. Hence they are called insulin sensitizers. 
Insulin sensitization is commonly understood as 
glucose clearance from plasma without additional 
inputs of insulin. In contrast, insulin resistance is 
thought to be poor glucose clearance despite presence 
of high amounts of insulin. For insulin sensitization, 
metformin is a commonly used drug for treating T2D. 
Metformin was approved by FDA in December 1994. 
Fiber foods and gums such as fenugreek seeds are 
found to bring glycemic control in diabetic subjects. 
Fiber because of its viscosity reduces circulating 
insulin levels[102,103]  
Oral hypoglycemic agents 
Most widely used oral hypoglycemic agents include 
Sulfonylureas. Thiazolidinediones are widely used oral 
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hypoglycemic agents which decrease glucose levels in 
type-2 diabetic patients by increasing the insulin 
sensitivity of target tissues. Metformin lowers blood 
glucose both by increasing insulin sensitivity and by 
decreasing hepatic gluconeogenesis. Metformin causes 
weight loss and a modest reduction in serum LDL 
cholesterol and triglyceride levels. Methadone is an 
opioid agonist which brings about its action by 
stimulation of μ-receptors as well as antagonism of 
glutaminergic N-methyl-Daspartate (NMDA) 
receptors. Methadone has been used to manage chronic 
pain and also as an analgesic in diabetic 
neuropathy[104,105].  
American Diabetes Association and The European 
Association for the Study of Diabetes recommended 
metformin as the first-line treatment for T2D. 
However, an annual failure of metformin therapy has 
been reported. Newer classes of agents are being 
developed with novel mechanisms of action: SGLT-2 
inhibitors, longer acting GLP-1 agonists, and PPAR α/γ 
dual and pan-agonists. Imeglimin belongs to a new 
class of drugs “the glimins” developed for the 
treatment of T2D with an objective to provide a safe 
and well-tolerated drug with unique pharmacological 
properties. Imeglimin has a different mechanism of 
action compared to other oral anti-diabetic compounds. 
Imeglimin is an innovative compound able to regulate 
multiple targets, including insulin resistant organs as 
well as β-cell failure[106,107]. 
In patients with T2DM Thiazolidinedione (TZD) 
therapy improves glycemic control both by 
strengthening beta cell function and enhancing tissue 
sensitivity to insulin by acting as peroxisome 
proliferator-activated receptor (PPAR) gamma agonists 
in liver and muscle. Insulin resistance and glucose 
intolerance was reduced with in time delivery of 
bromocriptine to the central nervous system. 
Bromocriptine-QR recently was approved by the US 
Food and Drug Administration (FDA) and is indicated 
as a supplement to diet and exercise to improve 
glycemic control in adults with T2DM. Bromocriptine-
QR acts as insulin sensitizer. Current guidelines for 
T2DM treatment suggested initial therapy with 
metformin and/or sulfonylurea. Hermes Florez et al. 
reported that in patients taking TZD with or without 
another OAA agent, bromocriptine-QR significantly 
improved glycemic control which persisted over one 
year of treatment and is not associated with increased 
risk for peripheral edema or weight gain which is 
common among those treated with TZDs. Guidelines 
suggest that glycosylated haemoglobin (HbA1c) should 
be maintained in diabetes mellitus at < 7%. Such levels 
of glucose control cannot generally be maintained with 
oral glucose lowering agents alone and often require 
use of insulin in addition to, or in place of, oral 
medications. The efficacy of present 
antihyperglycaemic agents is limited and most patients 
do not achieve glycatedhaemoglobin targets[108,109]  
Two glucagon-like peptide 1 (GLP-1) analogues are 
approved for use in Canada- liraglutide and exenatide. 
Similarly, two DPP-4 inhibitors are currently in use in 
Canada: saxagliptin and sitigliptin. Both GLP-1 
analogues and DPP-4 inhibitors stimulate insulin 
secretion, inhibit glucagon secretion in a glucose-
dependent manner and have a low risk of 
hypoglycaemia. Despite having much less tolerability 
than DPP-4 inhibitors, GLP-1 analogues are 
exceptional in achieving significant weight loss and 
lower A1C levels. Recently, a series of phosphonic 
acid-containing 4-aminobenzimidazoles were reported 
as adenosine-5‟- monophosphate (AMP) mimics, 
function as inhibitors of fructose1,6-bisphosphatase 
(FBPase), and demonstrated in vivo glucose-lowering 
activities in rodent models of T2DM[110,111]. 
Antiresorptive Drugs 
Antiresorptive drugs include the bisphosphonates and 
the selective estrogen receptor modulators (SERMs). 
Several studies have indicated that the anti-resorptive 
agent alendronate, a potent aminobisphosphonate, has 
been shown to increase bone mineral density (BMD) at 
the hip and spine and decrease the incidence of 
osteoporotic fractures in older women. Patients with 
diabetes having osteoporosis can tolerate anti-
resoprtive drugs including the bisphosphonates. 
Metformin has also been shown to have positive effects 
on bone turnover by improving metabolic control [112-
114].  
Tomoko Nakagami et al. showed that lipid-lowering 
treatment of statins reduced cholesterol synthesis but 
increased cholesterol absorption in patients with 
T2DM. Ezetimibe may be a useful therapeutic option 
to prevent micro- and macrovascular complications for 
dyslipidemia in patients with T2DM. Perioperative use 
of statins in patients undergoing carotid 
endarterectomy reduces perioperative mortality, 
myocardial infarction, and stroke and 2-year mortality. 
The guidelines recommend changes in lifestyle by diet 
and exercise as the first line of therapy in the primary 
prevention of CVD[115-117].  
Topical or subconjunctival injection of bevacizumab 
was found to be effective for inhibiting corneal 
neovascularization in diabetic patients. Pegaptanib is 
relatively safer than ranibizumab and bevacizumab. 
Intravitreal triamcinolone (IVTA) prevents choroidal 
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neovascularization, retinal neovascularization and 
proliferative vitroretinopathy and is a safe way of 
treatment to proliferative diabetic retinopathy. 
Combination therapy of topical steroids, NSAIDs (non 
steroidal anti-inflammatory drugs), and sub-tenon 
Triamcinolone acetate injection have shown to reduce 
or prevent macular edema. NSAIDs such as bromfenac 
and nepafenac are used in the treatment of post-
operative inflammation and ocular pain from cataract 
surgery. Nifedipine therapy is useful for patients with 
T2DM. It effects on platelet aggregation, lipid 
metabolism and cardiovascular functions. Nifedipine 
prevents calcium levels from increasing as much in the 
cells when stimulated, leading to less muscle 
contraction. It is reported that Vanadium, a trace 
element required for human body can reduce the blood 
glucose values of glycemia animals and has an effect 
on the treatment of diabetes complications. Vanadium 
can improve the learning and memory ability. 
Moreover, due to its relative lower toxicity and high 
hypoglycemic effect efficiency, organic vanadium may 
find clinical application in treating neuronal 
disturbances in the diabetic patients. Normal serum 
Zinc and good Zinc dietary intake improve osteoblastic 
function and prevent bone complications[118-120]. 
Herbal treatment for diabetes 
Bitter Gourd (Momordicacharantia), Bael 
(Aeglemarmelos), Gurmar Leaves 
(Gymnemasylvestrae), Fenugreek 
(Trigonellafoenumgraecum), Turmeric (Curcuma 
longa), Onion (Allium cepa), Nayantatra (Vincarosa), 
Neem (Azadirachthaindica), Garlic (Allium sativum), 
and sagargota (Ceasalpinia crista) are the most useful 
herbs for diabetic treatment. EA is a polyphenol 
naturally occurring in berries and nuts has shown many 
properties such as antioxidant, antimicrobial and 
antimutagenic agent. Leaf extract of Terminaliaarjuna 
(Combretaceae), an ayurvedic plant has recently been 
shown to possess antihyperglycemic activity in 
streptozotocin-induced diabetic rats. Several plant 
derived compounds have been shown to activate 
glucose transport through leaf extract leaf extract AMP 
Activated Protein Kinase (AMPK) activation Ex: 
Berberine. Curcumin, a principal curcuminoid of 
turmeric, salidroside, a bioactive component from 
Rhodiolarosea and cryptotanshinone, a 
quinoidditerpene were also reported to have AMPK 
mediated stimulatory effect on glucose uptake in 
adipocytes and muscles. The nutraceuticals developed 
from the soluble and fiber fractions of rice bran control 
both T1DM and T2DM[121-124].  
Physical training or exercise plays a key role in the 
prevention and treatment of diabetes by improving 
glucose tolerance and reducing insulin resistance. 
Regular exercise also reduces diabetes associated 
complications. The regular practice of the physical 
exercise has been considered important in the treatment 
of T2DM. Carla Ribeiro et al. showed that trained 
group animals have lower values of body weight 
evolution and body weight gain than sedentary groups. 
They also found higher blood glucose levels in 
sedentary alloxan groups. Besides pharmacotherapy, 
diabetic patients need to focus on the modulation of 
daily energy intake and expenditure (energy flux) 
through calorie restriction and brisk exercise to reduce 
weight (BMI)[125-127].  
Alcohol use 
Moderate levels of alcohol help in the treatment of 
diabetes. Hongmei L et al. study found quadratic curve 
(U- shaped) relationship between alcohol drinking and 
diabetes. Alcohol consumption of 26-50 g per day was 
inversely associated with risk of T2D, compared to 
non-drinking group, while drinking >50 g alcohol per 
day was not associated with T2D, which appeared to 
indicate that proper quantities of alcohol consumption 
may be a protective factor for T2D. Mechanisms of 
protective effect of proper quantities of alcohol 
consumption on T2D may be the same as on coronary 
heart disease[128,129]. 
Management 
The management of diabetes is so important for 
diabetics to understand because it helps in controlling 
the disease and also in preventing complications. 
Maintenance of normal blood glucose levels suppresses 
the onset and progression of vascular and neurological 
complications in T1D patients. Strategies such as diet, 
exercise and stress management have been strongly 
recommended and adopted to control T2D. Among 
those, diet has been seriously considered in controlling 
type- 2 diabetic hyperglycemia. Consumption of 
refined foods, polished cereals, and fat have been 
observed to influence the early onset of impaired 
glucose tolerance (IGT) which eventually leads to 
diabetes without any prior warning. Treatment of these 
cases with “insulin sensitizers” such as metformin 
appears to be promising in alleviating the associated 
hyperglycemic condition. The American Diabetic 
Association (ADA) and the European Association for 
the study of Diabetes (EASD) published an expert 
consensus statement on the approach to management of 
hyperglycemia in individuals with T2D. These 
guidelines recommend intervention at the time of 
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diagnosis with metformin in combination with lifestyle 
changes (MNT-medical nutriton therapy and exercise). 
Patients with T2D often have negative self-concepts, 
feel hopeless and, therefore, become lax about 
following their regimen. NasrinSamadi et al. study 
shows that quality of life education can have positive 
effect on diabetes self concept, and prevent physical 
and side effects of T2D. T2D can be totally controlled 
in some cases with diet and exercise. Prevention and 
treatment methods of obesity will help in the 
management and treatment of T2DM. Patients need to 
stop smoking, lose weight if obese. In patients with 
hypertension blood pressure should be reduced to less 
than 130/80 mm Hg. Cholesterol levels should be 
reduced to less than 70 mg/dL. Diabetic patients 
receiving long-term treatment with steroid eye drops 
are recommend monitoring their blood glucose levels 
because topical steroids can affect blood glucose 
levels. It is recommended to organize educational 
programs in hospitals for teaching diabetic patients 
hygienic care, diet, and compliance to physician‟s 
instructions regarding nutrition, exercise and 
medication[130-134]. 
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